Objective:

To report on the status and trends of advanced therapy clinical trials in the UK as of 2025.

Key Findings:

• The number of ongoing advanced therapy clinical trials in the UK increased to 193 in 2025 from 187 in 2024.
• 56% of the trials were early-stage, and 80% were commercially sponsored.
• The UK participated in 9% of all global trials and 57% of all European trials in 2025.
• Over 80% of ATMP clinical trials were in gene therapies, with a balance between ex vivo and in vivo approaches.
• Oncology trials accounted for 35% of the total, with growth noted in inflammation and immune system areas.

Interpretation:

The UK maintains a competitive edge in advanced therapy clinical research, supported by regulatory frameworks and increased funding thresholds.

Limitations:

• The data is limited to the UK and may not reflect global trends comprehensively.
• The focus on commercially sponsored trials may overlook non-commercial research efforts.

Conclusion:

The UK is well-positioned to leverage advanced therapy clinical trials for health and economic benefits, fostering an environment conducive to innovative therapies.